Purpose: To further our understanding of the biology and prognostic significance of various chromosomal 13q14 deletions in CLL.
INTRODUCTION
CLL has a varied clinical course and genomic aberrations are recognized as important to the diverse biological and clinical phenotypes of CLL (1) (2) (3) (4) . The most frequent chromosomal abnormality in CLL is commonly referred to as del13q14, which is detectable by FISH or SNP arrays in ~50% of all CLL (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) . While generally considered to be associated with favorable outcome, clinical experience and published data suggest that for a subset of CLL patients with this deletion outcome is not favorable. The reasons for this observation are not well understood and despite application of currently available measurable CLL risk factors, the reliable identification of the relatively unfavorable 13q14 patient subset is not possible.
While the 13q14 probe used in the CLL FISH panel identifies all typical 13q14 deletions in CLL, regardless of size, recent analyses of CLL genomes using SNP array platforms have resulted in the identification of substantial anatomical heterogeneity of 13q14 deletions in CLL (16) (17) (18) (19) . This anatomic heterogeneity is reflected in large versus small deletions, monoalleleic versus bialleleic deletions and various deletion extensions into centromeric and telomeric 13q regions. This heterogeneity provides clues to underlying effects of various 13q14 deletions on CLL biology and clinical behavior and makes it likely that more than one pathobiological mechanism underlies the existence of various 13q14 deletions in CLL.
To advance our knowledge of the effects of various CLL-associated 13q14 deletions on CLL patients, we have investigated prognostic effects of various 13q14 types and associated molecular events, including 13q14-resident miR 15a/16-1 expression levels, in a prospectively collected cohort of 255 CLL patients. In aggregate, our data provide solid support for a clinically meaningful separation of 13q14 deletions into subtypes that are defined as good prognosis type I (exclusive of RB1; ~30% of all CLL) and poor prognosis and written informed consent was obtained from all patients prior to enrollment. Data from 255 of these 266 patients were included in this report (5 patients enrolled on the study were excluded due to a diagnosis that was not CLL, and 6 patients had insufficient cryopreserved cells available for the analyses described).
Regardless of whether the subjects were originally diagnosed at our institution or another, we used the same CLL diagnostic criteria, based on the National Cancer InstituteWorking Group Guidelines for CLL (24) . Eligible patients needed to have an absolute lymphocytosis (greater than 5000 mature lymphocytes per µl), and lymphocytes needed to express CD19, CD23, sIg (weak) and CD5 in the absence of other pan-T-cell markers.
Time to first therapy (TTFT) and overall survival (OS) were based on the date of trial enrollment (the date of specimen procurement) or alternatively the diagnosis date, respectively (25) . CLL treatment was defined as cytotoxic chemotherapy and/or monoclonal antibody therapy for CLL. Clinical information, including Rai stage and all treatments given, was collected on all patients. Patient samples were characterized for selected CLLassociated chromosomal aberrations as a routine clinical test at the Mayo Clinic/Rochester using FISH. All biomarker assessments were performed on specimens procured at trial enrollment.
Cell Isolation

Flow cytometry sorting of CLL specimens
Research. Cryopreserved PBMCs from CLL blood specimens were prepared for FACS sorting into CD19+ and CD3+ cells as previously described (25) .
Preparation of Sample DNA
DNA used for SNP 6.0 profiling was extracted from FACS-sorted CD19+ and CD3+ cells as described (25) . For some cases (N=11), paired buccal DNA was used instead of CD3+ cell-derived DNA.
Array Data Analysis
The DNA was prepared for hybridization to SNP 6.0 arrays according to the manufacturers' recommendations. Affymetrix CEL files for each cell sample were analyzed using Genotyping Console software for initial quality control, followed by use of the Affymetrix "Birdseed" algorithm to generate tab-delimited SNP call files in text format. Call rates for the entire group of CD19+ samples included in this report were between 95.06% and 99.63%, with a mean call rate of 98.53%. Corresponding call rates for CD3+ or buccal DNA were between 93.14% and 99.66%, with a mean call rate of 98.49%.
Sample copy number heatmap displays were obtained from CEL files through use of the freely available software dChip (26) , adapted to run on a 64-bit computer environment. For genomic copy number analysis, we visually inspected parallel heatmap copy number images of CD19+ and paired CD3+/buccal DNA samples generated through dChipSNP and using the median smoothening functionality. Only those copy number changes detected in CD19+ and specificity of acquired copy number (aCNA) calling calculated based on data for del17p, The method used to nominate aCNAs using a statistical algorithm (27) is summarized in the Supplementary Methods section.
Exon resequencing of p53, RB1 and the 13q14-resident miR genomic locus.
Primers to amplify and sequence exons 2-10 of human p53 and all coding exons of RB1 and adjacent intronic sequences, including splice junctions, were designed using the primer 3 program (http://frodo.wi.mit.edu/primer3/) and sequence information was generated as described (28) . Mutations were confirmed using paired patient CD3+/buccal DNA as templates. The primers to amplify and sequence the 13q14-resident miR locus were: F: TTCTAAGCTCTGTTCAAAATGCT, R: TTGTGTTTCCTAACCTATAGCACTG and SEQ:
TAACAAGATTATCAATAATAC.
Determination of ZAP70 and IgV H status.
Determination of ZAP70 and IgV H status was performed as described (25) . the risk factor as potential dichotomization thresholds, and using univariate proportional hazards regression to estimate the corresponding hazard ratio. 
RESULTS
Patient Characteristics
Characteristics of the 132 CLL patients with typical 13q14 deletions as detected through SNP 6.0 profiling (identified within a prospectively enrolled and profiled cohort of 255 CLL patients) analyzed in this study are summarized in Table 1 stratified by 13q14 subtype and treatment status. Data for 123 CLL patients without typical 13q14 deletions are also summarized ( Table 1 ). Of the 132 CLL patients with typical 13q14 deletions patients, 100 (76%) were untreated (UT) and 32 (24%) relapsed (T) at the time of study enrollment.
Within the group of previously untreated patients, the distribution of important biomarkers across type I or II 13q14 lesions was well balanced: Rai stage 0: 45%/41%, Rai stages 1 or 2: 51%/53%, IgV H unmutated: 32%/29%, ZAP70 positive: 30%/26%, p53 exons 2-10 mutated: 11%/6%, del17p present: 7%/3% and del11q present: 6%/12%. The median time from diagnosis to enrollment and from enrollment to data analysis for previously untreated patients is detailed in Table 1 . All outcome analyses described below are based on SNP 6.0 array analysis and biomarker measurements that were performed on patient samples procured at study enrollment, thus avoiding confounding effects of longitudinal biomarker instability. Outcome was calculated using either the CLL trial enrollment date or the diagnosis date as the reference dates, as indicated, in order to minimize the effect of lead time biases.
The pathological anatomy of acquired subchromosomal genomic copy number changes spanning 13q14 in CLL as defined through SNP 6.0 array copy number profiling.
We catalogued all aCNAs on chromosome 13 in our CLL cohort using visual inspection of simultaneous displays of dChipSNP-based copy number estimates (heatmaps) Using a previously proposed classification schema for typical 13q14 deletions into types I and II (exclusive and inclusive of RB1, respectively), we detected 85 type I lesions and 54 type II lesions (including 7 CLL cases in which both lesion types were identified, existing on separate chromosomes) in this cohort. Further, the frequency of 13q14 type I and type II lesions in the entire CLL cohort (N=255) was 33% and 21%, respectively. Acquired uniparental disomy (aUPD) at 13q was identified in 7 CLL cases as previously described (18) . In all these cases the LOH region was very large (Supplementary Table 2 ). Six out of these seven cases also contained a region of copy loss at 13q14 (typical 13q14 deletions by FISH) while one case was associated with a homozygous miR16-1-5p mutation (see below).
A subset of CLL cases display very low miR16-1/15a cluster expression
Research. The 13q14-resident microRNAs miR16-1 and miR15a, located at 49,521 Mb physical position, are contributors to the biology of these lesions in CLL cells (18, (32) (33) (34) Mean normalized expression values of both miR16-1 and miR15a were substantially lower (miR15a ~8-fold and miR16-1 ~4-fold, respectively) in the CLL subgroup with more extensive del13q14 deletions (CN estimates <1) as opposed to the group with no del13q14.
For CLL cases with monoallelic 13q14 deletions and associated CN estimates ≥1 (the majority of such cases had CN estimates of ~1.2) as compared with cases without 13q14 deletions there was evidence for a gene dosage effect for miR15a expression (~1.3-1.9-fold lower) but no such effect for miR16-1 expression.
This combined data suggests that ~12-15% of CLL cases have very low miR16-1/15a levels and that the majority of CLL cases (~85%) display an overlapping range of expression of these miRs, with mild relative reductions in miR15 expression in monoallelically deleted 13q14 cases. We initially determined the prognostic value of SNP 6.0 array-defined 13q14 type I and type II deletions on overall survival in the CLL cohort (UT+T; N=132) using univariate analysis and either the CLL sample procurement/trial enrollment date or the CLL diagnosis date as the reference date. For both analyses, OS was significantly shorter for CLL patients with 13q14 type II lesions as opposed to patients with 13q14 type I lesions (Kaplan-Meier plots for these analyses are displayed in Figure 3A ,C). These findings were true in the analyses in which CLL cases that carried both 13q14 lesion types (N=7) where included and hierarchically assigned to type II status (shown) or alternatively, were excluded from analysis. Next, we analyzed the prognostic value of SNP 6.0 array-defined 13q14 type I and type II deletions on OS in the untreated subset of patients (UT; N=100) and again noted shortened survival of CLL patients with 13q14 type II as opposed to type I lesions (Kaplan-Meier plots for these analyses are displayed in Figure 3B,D) .
Finally, given that the nature of 13q14 deletion may also influence initial CLL disease progression, we analyzed TTFT estimates for the two 13q14 types but found no strong effects.
Deletion 13q14 type II are associated with a higher incidence of coexisting CLL-FISHdetectable chromosomal abnormalities than 13q14 type I lesions.
Next, we determined the frequency of 13q14 deletions of types I and II that are associated with coexisting genomic lesions as detected through i) CLL-FISH-25, or ii) SNP 6.0 array profiling (see below). We defined 13q14 deletions of either types I or II as "FISHcomplex" if they were associated with one or more additional abnormalities in the clinically used CLL-FISH panel (and if these abnormalities were detected in ≥25% of nuclei analyzed ; this is to remove low percentage lesions of unclear clinical or biological significance). Using these criteria, the following frequencies were measured: 1) 13q14-I frequency of ≥3 SNP 6.0 array-based subchromosomal aCNAs in our entire CLL cohort of 255 profiled patients was 20% (35) .
Given the known strong association of p53 mutations with elevated genomic complexity in CLL, we determined p53 exon 2-10 mutation frequencies in the CLL cases with 13q14 type I or II deletions and ≥2 additional SNP 6.0-based aCNAs: There were 16 cases with 13q14-I plus ≥2 aCNA, of which 7 (44%) were mutated in p53 exons 2-10 and there were 18 cases with 13q14-II plus ≥2 aCNAs, of which 6 (34%) were mutated in p53 exons 2-10.
Results of outcome analyses of 13q14 deletions of types I or II stratified by associated SNP 6.0 array profiling-detectable subchromosomal aCNA loads versus OS in CLL.
We proceeded with bivariate outcome analysis of 13q14 deletions of types I and II grouped by associated SNP 6.0 array-based subchromosomal aCNA status of ≥2 and ≥3, respectively, (CLL cases that carried both 13q14 lesion types where included and hierarchically assigned to type II status). Kaplan-Meier plots for these analyses are displayed in Figure 4A -H. From these analyses the following conclusions are supported: i) 13q14 lesions of either type with elevated associated aCNA counts were associated with a significantly worse prognosis than either type with no or additional aCNAs below indicated thresholds; and ii) 13q14 type II deletions were prognostically more adverse than 13q14 type I deletions, as evidenced by an accelerated disease course in cases with low associated complexity (aCNA ≤1 or ≤2, respectively), a finding that was particularly evident in CLL cases that were relapsed at the time of analysis (UT+T plots).
Next, we performed bivariate outcome analysis of 13q14 deletions of types I and II stratified by associated SNP 6.0 array-based subchromosomal aCNA status of ≥2 and ≥3, respectively, based on aCNA nominations that had been made using algorithmic aCNA 
Degree of 13q14 deletions and outcome in CLL
The degree of 13q14 deletions was quantified using the mean of 216 consecutive CN estimates based on probes located within 13q14 deletions and correlated with the outcome measures TTFT and OS for the group of 132 CLL patients with 13q14 deletions. The CLL cohort was dichotomized at every actual CN measurement and hazard ratios for short TTFT or OS were computed. As can be seen in Supplementary Figure 4A -H, a CN estimate of ~1 (N=32 for CN<1 and N=100 for CN≥1) and high CN cut-offs (the latter based on small N) optimally separated the cohort, suggesting that the degree of 13q14 deletion could have negative effects on CLL outcome once larger cohorts are studied (for this cohort the 95% confidence bands in grey overlapped a HR of 1)(36).
13q14-resident miR15a/-1 expression and outcome in CLL.
The relative expression levels of the 13q14-resident miRs as measured by Q-PCR (see above) were tested as a prognostic factor. The CLL cohort was dichotomized at every actual normalized miR expression measurement (actual delta CT values) and hazard ratios 
DISCUSSION
In this study, we have employed SNP 6.0 arrays to interrogate genomic DNA isolated from FACS-sorted CD19+ cells compared with either paired sorted CD3+ cells (96%) or paired buccal (4%) DNA from 255 CLL patients for acquired chromosomal copy number changes (aCNA) and LOH with a detailed focus on 13q14 deletions. The novel findings from this study are i) that 13q14 deletions have varying effects on CLL clinical behavior, with large 13q14 deletions (type II: inclusive of RB1) associated with an inferior prognosis; ii) that 13q14 type II deletions are frequently associated with additional aCNA (a total aCNA count of ≥3 was detected in ~35% of cases) (35) ; iii) that ~10-15% of CLL with bialleleic 13q14 deletions display markedly reduced miR15a/16-1 levels but that the effect of monoallelic miR loss on miR expression is subtle and only demonstrable for miR15a; iv) that the relative expression levels of the 13q14-resident miRs do not substantially affect CLL prognosis; v) that a few CLL cases with 13q14 type II deletions carry RB1 frameshift mutations and therefore are RB1 null, and, vi) that rare CLL cases harbor acquired mutations in miR16. 1. This study is characterized by several methodological strengths, including paired (CD19+ versus CD3+) array analysis for all CLL samples, ultra-high-purity (sorted) cell sources as a source of DNA and RNA (for miR expression analysis) and a rigorous and conservative genomic copy number data analysis schema that had previously been externally validated using FISH (27) . The analysis of paired samples is of particular importance for the accurate determination of genomic complexity in cancer cell genomes in the setting of ultra-high-resolution SNP arrays, given that the vast majority of CNVs are <1Mb in length. In all, our approach results in very high specificity and sensitivity for aCNA, thus avoiding problems for the precision of genomic clinical correlative analysis resulting from under-or overcalling of genomic lesions. As part of the work presented here, we provide refined estimates for optimal physical separation cutoffs for 13q14 deletions into prognostically significant subtypes. From a practical perspective, routine inclusion of a probe for RB1 or genes located within 300-500kb telomeric to RB1 should reliably identify CLL patients carrying more adverse 13q14 subtypes (17) .
Our novel identification of somatically acquired RB1 null states, including somatically acquired RB1 mutations, provides evidence that for a subset of 13q14 deletions, RB1 is a relevant target gene. Furthermore this conclusion is supported by the well-studied effects of RB1 on cell cycle control and genomic stability (37) . However, given the identification of proven through longitudinal analysis (inclusive of the hypothesis that 13q14 type II deletions arise during CLL disease evolution). Regarding the conclusion that 13q14 type II deletions constitute a factor associated with and contributory to more aggressive CLL, we were able to demonstrate that these lesions are disproportionally associated with elevated genomic complexity in CLL: a trait associated with aggressive CLL (25) . It is, however, important to note that additional studies with substantially larger patient numbers are needed to be able to measure the relative contribution of 13q14 deletion subtypes versus other factors known to affect CLL clinical behavior.
One of the current, still speculative interpretations of the combined available data on 13q14 deletions in CLL is that short 13q14 deletions affect genes that confer a growth or survival/anti-apoptotic advantage on CLL cells, while longer 13q14 deletions are part of CLL disease evolution and degeneration into more aggressive subtypes; the latter would be due to increased genomic instability (as also seen with 17p and 11q deletions) and an ensuing potential for outgrowth of more aggressive CLL subclones (35, 38) and likely other, as-yet unidentified mechanisms.
In summary, our data demonstrate that 13q14 deletions in CLL are biologically and prognostically distinct entities and that routine clinical identification of 13q14 type I and II deletions would allow for refined CLL patient risk stratification.
Research. 
